Trial NCT00745823

View at ClinicalTrials.gov 
Org. Study IDs: 0518-071
Secondary IDs: 2008_543 CTRI/2009/091/000145

Last trial update was posted on 2017-03-21

MeSH Interventions

Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Raltegravir Potassium

MeSH Conditions


Other Conditions

HIV

Stopping Reasons

Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg once daily versus raltegravir 400 mg twice daily

Limitations And Caveats

The study was terminated before the 96-week efficacy analysis. Adverse event data were collected for the entire treatment period up to a maximum of Week 108, which defines the Overall Study period.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID